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Abstract
Background: Mantle cell lymphoma (MCL) is an incurable B cell lymphoma and accounts for 6%
of all non-Hodgkin's lymphomas. On the genetic level, MCL is characterized by the hallmark
translocation t(11;14) that is present in most cases with few exceptions. Both gene expression and
comparative genomic hybridization (CGH) data vary considerably between patients with
implications for their prognosis.
Methods: We compare patients over and below the median of survival. Exploratory principal
component analysis of gene expression data showed that the second principal component
correlates well with patient survival. Explorative analysis of CGH data shows the same correlation.
Results:  On chromosome 7 and 9 specific genes and bands are delineated which improve
prognosis prediction independent of the previously described proliferation signature. We identify
a compact survival predictor of seven genes for MCL patients. After extensive re-annotation using
GEPAT, we established protein networks correlating with prognosis. Well known genes (CDC2,
CCND1) and further proliferation markers (WEE1, CDC25, aurora kinases, BUB1, PCNA, E2F1)
form a tight interaction network, but also non-proliferative genes (SOCS1, TUBA1B CEBPB) are
shown to be associated with prognosis. Furthermore we show that aggressive MCL implicates a
gene network shift to higher expressed genes in late cell cycle states and refine the set of non-
proliferative genes implicated with bad prognosis in MCL.
Conclusion: The results from explorative data analysis of gene expression and CGH data are
complementary to each other. Including further tests such as Wilcoxon rank test we point both to
proliferative and non-proliferative gene networks implicated in inferior prognosis of MCL and
identify suitable markers both in gene expression and CGH data.
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Background
Mantle cell lymphomas (MCL) make up about 6% of all
cases of non-Hodgkin's lymphomas. They occur at any age
from the late 30s to old age, are more common in the over
50 years old population and three times more common in
men than in women. Morphologically, MCL is character-
ized by a monomorphic lymphoid proliferation of cells
that resemble centrocytes. MCL is associated with a poor
prognosis and remains incurable with current chemother-
apeutic approaches. Despite response rates of 50–70%
with many regimens, the disease typically relapses and
progresses after chemotherapy. The median survival time
is approximately 3 years (range, 2–5 y); the 10-year sur-
vival rate is only 5–10%.
The characteristic translocation t(11;14) leads to overex-
pression of Cyclin D1 in the tumor cells which therefore
comprises an excellent marker in the diagnostic setting
[1]. The present study is an effort to improve molecular
insights and markers of the disease [2-6] to improve the
diagnosis and potential therapeutic strategies. We used
gene expression data from 71 cyclin D1-positive patients
and coupled these to data on their corresponding chro-
mosomal aberrations (n = 71). We found molecular
markers in addition to cyclin D1 and characteristic anti-
gens (shared with blood cells from which the tumor may
develop) CD5, CD20 and FMC7 with the aim to better
delineate the regulatory network regulated differently in
MCL.
Starting from the proliferation signature [6] we compare
long and short living patients subgroups "s" (survivor,
above median of survival) and "b" (bad prognosis, below
median of survival). Exploratory analysis of gene expres-
sion and CGH data shows new genes differentiating both
subgroups, proliferation associated genes and non-prolif-
erative genes. For clinical application a seven gene predic-
tor is derived from these gene markers, distinguishing
patients with good or bad survival prognosis. A Wilcoxon
rank sum test on CGH data identifies specific changes on
chromosome 9 and 7.
Methods
Data and Materials
MCL gene expression data (n = 71) were obtained from
cDNA arrays containing genes preferentially expressed in
lymphoid cells or genes known or presumed to be part of
cancer development or immune function ("Lymphochip"
microarrays [7]; data have been deposited at NCBI's Gene
Expression Omnibus data repository under GEO series
accession number GSE10793. We give also the resulting
gene expression ratios [see Additional file 5] and the prog-
nosis assigned to patients [see Additional file 6]. The data-
set is completed by comparative genomic hybridization
(CGH) data for each patient (n = 71). The samples were
collected from cyclin D1-positive patients of several hos-
pitals in the "Lymphoma and Leukemia Molecular Profil-
ing Project" (LLMPP) [6].
Statistical analysis
Most of the statistical analyses were performed using the
"Genome Expression Pathway Analysis Tool" (GEPAT).
This is a web-based platform for annotation (allowing
also extensive re-annotation of the data), analysis and vis-
ualization of microarray gene expression data [8] includ-
ing genomic, proteomic and metabolic features.
The database performs the analyses applying Bioconduc-
tor [9], an open source software for the analysis and com-
prehension of genomic data, based on the R
programming language [10].
For identification of differentially expressed genes, GEPAT
uses the "limma" package which offers moderate t-statis-
tics [11,12]. It fits linear models on the gene expression
values of each gene with respect to the groups which are
compared. After that empirical Bayes shrinkage of the
standard errors is performed. Due to its robustness the
method can be applied to experiments with a small
number of samples. To correct for multiple testing it offers
three options, we chose the method by Benjamini and
Hochberg [13].
For identifying all protein-protein network interactions
GEPAT uses the "Search Tool for the Retrieval of Interact-
ing Genes/Proteins" (STRING) [14]. The STRING data-
base comprises known and predicted protein-protein
interactions. The interaction information arises from
genomic context, experiments, other databases, coexpres-
sion and textmining.
For explorative correspondence analysis and principal
component analysis, functions from the R package "Mod-
ern Applied Statistics with S" (MASS) was applied [15]. A
constrained or canonical correspondence analysis (CCA)
[16] was performed using the vegan package [17].
The Wilcoxon rank sum test [18], a non-parametric statis-
tical test, was applied to the CGH data. It tests here each
of the chosen bands against the null hypothesis that there
is no statistically significant difference between our pro-
posed two MCL patients "b" and "s". The R package "sur-
vival" is used to calculate all Cox regression hazard
models [19,20]. It examines the correlation between the
given measurements and the survival data. For the explor-
atory analysis of the CGH data as well as for the new pre-
dictor of MCL overall survival, we used the Wald test to
determine the significance of the association between the
model and the outcome.BMC Cancer 2008, 8:106 http://www.biomedcentral.com/1471-2407/8/106
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Results
Exploratory analysis and lymphoma prognosis
The survival time itself is the most obvious and biological
meaningful parameter in which subgroups should show a
big difference for realizing individual clinical treatment.
We selected 3.000 genes with the highest variance and
applied correspondence analysis (Figure 1). We found (71
MCL patients) that already the second axis separated
almost perfectly the longer and the shorter living patients
above and below the median of survival. Furthermore,
this coincides well with the median of the proliferation
signature [6] values in a multidimensional data space (see
Methods). This finding was re-examined by exploratory
data analysis of the genes of the proliferation signature
and a huge amount of further genes. We ranked a total of
71 MCL patients according to their proliferation signature
values and separated them according to the median. We
define two groups – "s" for small and "b" for big prolifer-
ation signature with big difference in the survival time.
Patients with a high proliferation signature value live
shorter on average, than patients with a low proliferation
signature value.
To each single chromosome of the CGH data exploratory
data analysis was applied, correspondence analysis [see
Additional file 1] and principal component analysis (Fig-
ure 2). Both methods are useful for exploring information
and structures in data in order to get a first and unbiased
impression. Principal components analysis reduces multi-
dimensional data sets to lower dimensions for analysis.
Correspondence analysis works similarly, but scales the
data, such that both rows and columns can be visualized
in one plot. Results show a strong correlation for four
bands of chromosome 9, 9p24, 9p23, 9p22 and 9p21 and
above median ("s") or below median patient survival
("b").
In the correspondence analysis plot [see Additional file 1],
the four bands mentioned before attract most patients of
the subgroup "b" and the 1st factor axis separates almost
Principal Component Analysis of chromosome 9 bands sepa- rating the "s" and "b" group Figure 2
Principal Component Analysis of chromosome 9 
bands separating the "s" and "b" group. The second 
principal component separates almost all patients of the sub-
group "b" from the remain. They are grouped together close 
to the first four vectors, corresponding to the first four 
bands 9p24, 9p23, 9p22, 9p21, which go into the same direc-
tion and are of similar length. Remarkable are the vectors of 
the bands 9q33 and 9q34. They also are of similar length and 
go exactly into the same direction. Along their length, they 
congregate almost all patients of the type "s". This leads to 
the assumption, that the first four and the last two bands of 
chromosome 9 play a crucial role for "s" and "b" classifica-
tion.
í í  
í



í









&RPS
&
R
P
S


b
s
s
s
s
b
b
s
b
s s b s s b s
b
b s s s
b
s
b b b
b
b b
b
b b b b s
b
b
b b
s
b b s s b s
s
b
s b s
s
b s
s s s s b s b
b
s s b
b
s s s s
í í í   
í

í

í




S
S
S
S
S S S
T T T
T
T
T T
T
T
Correspondence analysis identifies the two Mantle cell lym- phoma subgroups Figure 1
Correspondence analysis identifies the two Mantle 
cell lymphoma subgroups. The gene expression data are 
projected on the first two principal axes. The patients can be 
clearly separated by this exploratory analysis considering the 
3.000 genes (red dots) of the highest variance. In the corre-
spondence plot this is indicated by the horizontal separation 
line. The patients are labelled with "s" and "b" which repre-
sent the separation by the median of the proliferation signature 
into two different entities. Patients with a proliferation signa-
ture value smaller than the median are marked with ”s“ and 
the other patients with ”b“.
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completely the two groups. Bands 9q33 and 9q34, are
located relatively far away from the remaining ones. In
Figure 2 the second principal component groups almost
all the "b" – patients near the four bands 9p24, 9p23,
9p22, 9p21 with vectors of similar length and similar
direction. The vectors of 9q33 and 9q34 include along
their lengths almost all "s" samples. These results indicate
that these six bands of chromosome 9 correlate with good
and bad survival between patients. The principal compo-
nent 1 is an interesting main component, carrying 51% of
the variance, but non-trivial to link to a known phenotype
(we investigated different possibilities including sex dif-
ferences, cancer sub-types, patient accrual and correlation
with different gene signatures).
Further exploratory data analysis was performed to merge
the survival time and the CGH data by the Cox regression
hazard model. A univariate Cox regression hazard model
was performed on all available bands of the CGH data of
all 71 patients. The mentioned four bands of chromo-
some 9 delivered amongst others the most significant
results. The resulting bands are "9p24", "9p23", "9p22",
"9p21", "9q31" and "9q32". These comprise the first four
bands found on chromosome 9 by the analyses before.
A compact predictor of survival with seven genes
Exploratory analysis pointed to differences between
longer and shorter living MCL patients, but rather than
forming two distinct subgroups, the patients constitute a
coherent continuum. Therefore, the results of the explora-
tory analysis above were not additionally confirmed by
classification tools. However, the differences in gene
expression above and below the median of survival corre-
late well with different gene signatures identified before
(proliferation signature) as well as with the new ones
described in our study (non-proliferative signatures, see
below). To improve survival predictions we further
searched with univariate Cox regression hazard analysis
for highly significant genes, which correlate strongly with
the overall survival time. The cox regression was applied
to all data points. However, the first 50 MCL samples
served as training set for classification by gene signatures
and the remaining data (21 patients) for validation. The
idea was here to have a large training data set, but still
keep a third of the available data for validation.
A four gene predictor with the genes CDC2, ASPM, tubu-
lin-α and CENP-F reported in [6] could not be tested, as
after reannotation by GEPAT [8], mapping of CENP-F
seemed uncertain. Predictors with 4, 5 or 6 genes deliv-
ered not the same predictive power as the proliferation
signature [6] (data not shown). The prediction power was
calculated from the correct classification and misclassifi-
cation for patients over or below the median of survival
for 69 patients (the two patients with the median value
were excluded).
However, we identified a set of seven genes delivering
similar good prognosis separation. It includes (i) the well
known key cell cycle kinase CDC2 [21,22], (ii) the "cell
division cycle 20 homolog" (CDC20) required for ana-
phase and chromosome separation [23] and (iii) the sal-
vage pathway gene HPRT1 (hypoxanthine
phosphoribosyltransferase 1), three genes from the 20
genes proliferation signature of Rosenwald [6]. We get
improved prediction power including four additional
genes (Table 1): (i) centromere protein E (CENPE), a
kinesin-like motor protein; it accumulates during G2
phase of cell cycle for chromosome movement or spindle
elongation [24]. (ii) BIRC5 (baculoviral IAP repeat-con-
taining 5 gene), an inhibitor of apoptosis (IAP gene fam-
ily) is expressed in most tumours and in lymphoma [25],
participates in the spindle checkpoint and associates with
AURKB [26]. (iii) ASPM (abnormal spindle homolog) is
essential for normal mitotic spindle function [27]. (iv)
Insulin-like growth factor 2 mRNA binding protein 3
(IGF2BP3), is found in the nucleolus, is over-expressed in
human tumours and represses IGF2 during late develop-
ment [28-30].
The seven genes were used to calculate a multivariate Cox
regression hazard model and with its coefficients, a gene
Table 1: The genes of the survival predictor
Acc Gene EnsemblID Official full name
6558 CENPE ENSG00000138778 Centromeric protein E
7495 CDC20 ENSG00000117399 Cell division cycle protein 20 homolog
7892 HPRT1 ENSG00000165704 Hypoxanthine-guanine phosphoribosyltransferase
7019 CDC2 ENSG00000170312 Cell division control protein 2 homolog
7376 BIRC5 ENSG00000089685 Baculoviral IAP repeat-containing protein 5
6422 ASPM ENSG00000066279 Abnormal spindle-like microcephaly-associated protein
5923 IGF2BP3 ENSG00000136231 IGF-II mRNA-binding protein 3
Univariate Cox regression hazard analysis revealed these seven genes best correlating with the survival time (see Material and Methods). The first 
column indicates the gene accession number in the data set (Acc), the second the gene name, followed by the Ensembl identifier and the official full 
name. The genes are ordered by their significance in decreasing order. CENPE is the most significant gene.BMC Cancer 2008, 8:106 http://www.biomedcentral.com/1471-2407/8/106
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expression based survival estimator separated all 71
patients into two subgroups. Two patients had exactly the
median of survival and were excluded in this comparison,
56 agreed with the classification according to the gene sig-
natures, 13 did not. Compared to the proliferation [6] sig-
nature's ability to distinguish patients with good and bad
survival prognosis (Figure 3), the seven gene predictor
does it similarly well (Figure 4). The correlation between
this classification and the "s" and "b" groups of the prolif-
eration signature is overall about 0.62 and in our valida-
tion set (patients 51 – 71) it is 0.81.
A correspondence analysis of the 3.000 genes with the
highest variance showed clear clustering of patients with
good or bad prognosis, respectively (Figure 1). Using pro-
liferation signature [6] (Figure 3), samples show a little
overlap, but are again separated clearly.
Taken together, these results show that the seven gene pre-
dictor is able to distinguish patient prognosis as well as
the complete proliferation signature, but with less effort.
Protein networks and interactions differently regulated in 
good and bad prognosis tumors
We found a dense regulatory network of interacting genes
correlated with prognosis. Applying a moderate t-test, the
well known cell division cycle 2 gene (CDC2/CDK1) for
G1 to S and G2 to M transition [31,32] shows the most
significant difference between the longer living "s" and
the shorter living "b" patients (Table 2). Furthermore, its
interaction partners according to HPRD database [33]
show a significant up or down regulation comparing good
and bad surviving patients (Figure 5), e.g. WEE1 and
CDC25. Moreover, aurora kinases A, B [34] and BUB1
kinase activating the spindle checkpoint [35], are differ-
ently regulated between shorter and longer living patients.
However, there are further genes involved in this network
of directly interacting genes differently regulated in good
or bad prognosis patients (Figure 5; Figure 6) such as (i)
"proliferating cell nuclear antigen" (PCNA), a cofactor of
DNA polymerase delta, helps to increase the processivity
of leading strand synthesis during DNA replication in
group "b". Because of its ability to interact with multiple
partners, it is involved in Okazaki fragment processing,
DNA repair, translation, DNA synthesis, DNA methyla-
tion, chromatin remodelling and cell cycle regulation
[36]. (ii) E2F transcription factor 1 (E2F1), this protein
can mediate both cell proliferation and p53-dependent/
independent apoptosis [37]. It is lower expressed in group
"s". (iii) Nucleolin is an abundant multifunctional phos-
phoprotein of proliferating and cancerous cells [38-41]
and highly expressed in "b".
Correspondence analysis separates two MCL subgroups  derived by the 7 genes survival predictor Figure 3
Correspondence analysis separates two MCL sub-
groups derived by the 7 genes survival predictor. The 
3.000 genes with highest variance (red dots) separate 
between the two subgroups, which were delivered by the 
seven gene predictor and are drawn as "s" and "b". They 
were separated by the median of the predictor values. In 
contrast to the proliferation signature based predictor (Fig-
ure 1), the patients here show a little more overlap, but clus-
ter clearly.
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Kaplan Meier plot of survival data in MCL subgroups Figure 4
Kaplan Meier plot of survival data in MCL subgroups. 
The x-axis denotes the course of time in years and the y-axis 
marks the probability of survival. Both, the proposed prolif-
eration signature (black) and the seven genes predictor 
(grey) separate clearly two risk groups in the survival data. 
The overlap between the patients of the two classifications is 
relatively high.
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Interaction partners of CCND1 are also significantly dif-
ferently expressed (Figure 7): CCND1 and CDK4 are
assumed to be involved in cell cycle progression of MCL,
MYC is suspected of increasing MCL's proliferation rate.
FOS, JUN and MYBL2 are partly known to play a role in
cancer, but not explicitly in MCL. FOS ("v-fos FBJ murine
osteosarcoma viral oncogene homolog") and JUN ("jun
oncogene") are weakly downregulated in "b". Other inter-
action partners such as MYC ("V-myc myelocytomatosis
viral oncogene homolog (avian)"), MYBL2 ("V-myb mye-
loblastosis viral oncogene homolog (avian)-like 2"),
CDK4 ("Cyclin-dependent kinase 4") and CDK6 show
higher gene expression values in bad prognosis patients
below the median of survival.
Moreover, there are some genes with similar significance
and expression difference, associated with other functions
(Table 3). Most of them are associated with DNA metab-
olism. Three of them, "suppressor of cytokine signaling 1"
(SOCS1), "tubulin, alpha 1b" (TUBA1B), and "CCAAT/
enhancer binding protein (C/EBP), beta" (CEBPB) are
mentioned here. CEBPB, is a transcription factor. It plays
an important role in immune and inflammatory
responses [42]. Additionally it can stimulate the expres-
sion of the collagen type I gene. TUBA1B encodes for an
important part of the microtubules. SOCS1 is a member
of cytokine-inducible inhibitors of signaling [43] and
inhibits protein kinase activity.
CGH data reveals new genes implicated in MCL outcome
We applied the Wilcoxon rank sum test on the CGH data
and compared the patients with good "s" and bad progno-
sis "b" (over and below median of survival). The null
hypothesis corresponds to no differences between the two
entities. The resulting p-values for every band of chromo-
some 9 are compared in Figure 8. They show strongly the
significance of the first four bands 9p24, 9p23, 9p22 and
9p21. On these bands are MCL related genes such as "cyc-
lin-dependent kinase inhibitor 2B" (CDKN2B) and "cyc-
lin-dependent kinase inhibitor 2A" (CDKN2A). TP53
mutations are associated with the blastoid variant of MCL
and with a worse prognosis. The bands 9q33 and 9q34 are
Protein interaction network of significantly different expressed genes Figure 5
Protein interaction network of significantly different expressed genes. The genes encoding these proteins show a sig-
nificant expression difference between the "s" and "b" group (moderate t-test). Remarkably CDC2 is involved in a small inter-
action network of protein kinases and almost all of these interaction partners (CDC25, WEE1, AURKB, AURKA, BUB1) are 
associated with the cell cycle.BMC Cancer 2008, 8:106 http://www.biomedcentral.com/1471-2407/8/106
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less significant. To visualize this result more clearly we
plot the densities of the p-values [see Additional file 2]. A
peak in the density indicates significant bands of the Wil-
coxon test.
The Wilcoxon rank sum test showed similar results for
chromosome 7. Here, the bands 7p21, 7p15, 7p14 are
potentially related to the classification of "s" and "b"
patients. Now the log p-values and their densities are plot-
ted against the bands in Figure 9, the density plot of p-val-
ues for chromosome 7 is also shown [see Additional file
3]. The explorative analyses of chromosome 7 could not
show such a clear relation as in chromosome 9.
Specific gene expression differences in patients with good
or bad prognosis are well supported by the CGH data of
chromosome 9. We checked the location of the signature
genes as we wondered if they were on chromosome 7 or
9, however this was not the case. Also the genes of the
gene network in Figure 6 are located elsewhere. No result
mentioned before could explain the relationship between
the subgroups and the subgroup-separating CGH data of
chromosome 9. We thus investigated the gene expression
data of these bands. Again a moderate t-test was applied
to rank genes differentially expressed between "s" and "b".
The top five are listed in Table 4, e.g. the "Heat Shock 70
kDa protein 5" and a catalytic subunit of "Protein Phos-
phatase 6". Several of their functions implicate them to be
critical in cancer development. Their genomic position
revealed a quite remarkable clustering of these genes [see
Additional file 4]. Three of the genes seem to be located
very closely to each other. The "heat shock 70 kDa protein
5" (HSPA5), also referred to as 'immunoglobulin heavy
chain-binding protein' (BiP) targets misfolded proteins
for degradation, and has an anti-apoptotic property. It is
induced in a wide variety of cancer cells and cancer biopsy
tissues and contributes to tumor growth and confers drug
resistance to cancer cells [44]. The PPP6C gene encodes
for a catalytic subunit of the Ser/Thr phosphatases, the
"protein phosphatase 6 catalytic subunit" [45]. The pre-B-
cell leukemia transcription factor 3 (PBX3) shows exten-
sive homology to PBX1, a human homeobox gene
involved in t(1;19) translocation in acute pre-B-cell leuke-
mia. But in contrast to PBX1 the expression of PBX3 is not
restricted to particular states of differentiation or develop-
ment [46]. It is also known that if HoxB8, a homeobox
gene identified as a cause of leukemia, binds to the Pbx
cofactors it blocks differentiation in certain cell types [47].
"Prostaglandin-endoperoxide synthase 1" (PTGS1) is the
key enzyme in prostaglandin biosynthesis, and is also
known to play a role in the human colon cancer [48,49].
The expression of the alternative splice variants is differen-
tially regulated by cytokines and growth factors [50-52].
Very little is known about "quiescin Q6-like 1"
(QSCN6L1), except its major role in regulating the sensi-
tization of neuroblastoma cells for IFN-gamma-induced
apoptosis [53]. A similar clear clustering as on chromo-
some 9 could not be detected on chromosome 7.
Discussion
Several different marker genes and events have been pro-
posed for MCL, e.g the translocation t(11;14)(q13;q32)
[1], immunohistochemically [54] and Repp86 proteins as
Table 2: Most significant genes separating good (s) and bad (b) prognosis
Acc Gene Fold change p-value EnsemblID
7019 CDC2 1.3737029 1.8651454E-13 ENSG00000170312
6632 NP_057427.3 0.94384 3.4574367E-13 ENSG00000117724
3399 UHRF1 1.1446086 1.5513529E-12 ENSG00000034063
5112 NP_060880.2 1.0916529 1.5513529E-12 ENSG00000123485
6994 AURKB 1.4594886 1.5513529E-12 ENSG00000178999
6388 MKI67 1.5062114 1.7304206E-12 ENSG00000148773
6721 Q9Y645_HUMAN 1.2185314 3.2408542E-12 ENSG00000140451
7024 BUB1 1.2488679 3.2408542E-12 ENSG00000169679
6392 NP_057427.3 1.3208085 3.2902188E-12 ENSG00000117724
5726 MKI67 1.4871315 3.6012686E-12 ENSG00000148773
6029 NP_057427.3 1.2980943 5.249176E-12 ENSG00000117724
7423 BIRC5 1.3726515 6.49239E-12 ENSG00000089685
4985 ASPM 1.3310171 7.281489E-12 ENSG00000066279
5754 KIF23 1.2461857 1.6424877E-11 ENSG00000137807
5271 ASPM 1.3205649 2.2259293E-11 ENSG00000066279
6104 KIF23 1.1683029 2.4981522E-11 ENSG00000137807
The most significant differentially expressed genes regarding good ("s") or bad ("b") prognosis determined with a moderate t-test. P-values were 
corrected for multiple testing [13]. The gene "cell division cycle 2" (CDC2), which is important for the transition G1 to S and G2 to M shows the 
biggest difference in gene expression between the two groups. This indicates that these cell cycle transitions are part of the difference between the 
two groups.BMC Cancer 2008, 8:106 http://www.biomedcentral.com/1471-2407/8/106
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Differences in gene expression of interaction partners of CDC2 in MCL subgroups Figure 6
Differences in gene expression of interaction partners of CDC2 in MCL subgroups. In this network figure, red indi-
cates high expression and blue low expression in the subgroup "b" of the proliferation signature. White indicates no gene 
expression difference and grey the unavailability of the gene in our data set. "Cell division cycle 2" (CDC2) gene interacts in dif-
ferent manners with "cyclin D1" (CCND1), "cell division cycle 25C"(CDC25C), "proliferating cell nuclear antigen"(PCNA), 
"E2F transcription factor 1"(E2F1) and WEE1. CDC2 and CCND1 are both required for the G1/S transition. The genes WEE1 
and CDC25C phosphorylate and dephosphorylate the complexes bound with CDC2 in a cell cycle regulating manner. The 
"proliferating cell nuclear antigen" (PCNA) is involved in DNA replication whereas "E2F transcription factor 1" (E2F1) controls 
cell cycle and mediates cell proliferation and apoptosis. A cell cycle regulated transcription activator "Nucleolin" (NCL) shows 
little difference.BMC Cancer 2008, 8:106 http://www.biomedcentral.com/1471-2407/8/106
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Protein interaction partners of CCND1: Different gene expression in MCL subgroups Figure 7
Protein interaction partners of CCND1: Different gene expression in MCL subgroups. The colors red, blue and 
grey mean "over expressed", "down regulated" (in "b") and "not available in the data set". FOS encodes for a leucine zipper 
protein and plays a role in regulation of cell proliferation, differentiation, transformation and tumorigenesis [58]. The JUN pro-
tein interacts directly with specific target DNA sequences to regulate gene expression [59] and is involved in tumorigenesis by 
cooperating with oncogenic alleles of Ras, an activator of the mitogen activated protein kinases [60]. MYC and MYBL2 play a 
role in cell cycle progression and act as transcription factors. MYC is also associated with apoptosis, cellular transformation, 
cell growth, proliferation, differentiation, and a variety of hematopoietic tumors, leukemias and lymphomas [61, 62, 63], and 
was part of the original proliferation signature [6]. MYBL2 has been shown to play a role in the G1/S transition [64] and prolif-
eration [65] and is known to be regulated by CCND1 [66, 67]. CDK4 and CDK6 are important regulators of cell cycle transi-
tion from G1 to S, phosphorylate, and thus regulate the activity of tumor suppressor protein Rb [68].BMC Cancer 2008, 8:106 http://www.biomedcentral.com/1471-2407/8/106
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a proliferation markers [55] and increased levels of cyclin
D1.
The present study consolidates gene expression and CGH
data regarding MCL subgroups with good or bad progno-
sis to an overall picture. These subgroups are indicated
and confirmed by exploratory analyses. This picture
shows as yet unknown relations and differences between
patients from these groups.
Correspondence analysis is an unsupervised tool to
project high dimensional data into lower dimensional
subspaces. Surprisingly, its second component separates
well the shorter and longer living patients according to the
median of survival. This result is in close agreement with
the median of the outcome predictor score derived by the
proliferation signature [6] as a discriminator.
A new predictor of survival with similar predictive power
as the proliferation signature of 20 genes [6] was devel-
oped requiring gene expression values of only seven
genes. With the key genes CDC20, HPRT1 and CDC2 the
seven-gene-predictor matches with three genes from the
20 genes proliferation signature. Moreover, the four genes
CENPE, BIRC5, ASPM and IGF2BP3 add to its predictive
power and are associated with chromosome movement,
inhibition of apoptosis and tumors. It was shown that a
four gene predictor (CDC2, ASPM, tubulin-alpha, CENP-
F) [6] is also able to predict length of survival with high
statistical significance. Besides the fact, that the prolifera-
tion signature is more efficient and powerful than the four
gene model, our model meets extensive re-annotation of
the genes through the clone IDs.
These CGH data support the association of alterations in
chromosomal regions and outcome of MCL patients.
Gene expression analysis comparing long and short sur-
viving patients delivered cell cycle related genes and their
protein-protein interactions. A dense interaction network
differently regulated in good or bad prognosis includes
CDC2 and interaction partners for cell cycle control and
proliferation (CCND1, CDK4, MYC and E2F1; CDC25,
WEE1, AURKB, AURKA, BUB1, PCNA, FOS, JUN and
MYBL2). However, we identified furthermore non prolif-
P-values of the Wilcoxon test for the bands of chromosome  7 Figure 9
P-values of the Wilcoxon test for the bands of chro-
mosome 7. The Wilcoxon test was applied to all bands of 
chromosome 7 over the two groups "s" and "b". The bands 
of chromosome 7 (x-axis) are plotted against the log p-values 
(y-axis). Three bands show a very low p-value: 7p21, 7p15, 
7p14. As the four bands of chromosome 9, they could have a 
relation to the "s" – "b" classification.
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Table 3: Genes separating good (s) and bad (b) prognosis not associated with cell cycle and proliferation association
EnsemblID Gene p-value Fold change
ENSG00000185338 SOCS1 2.3029981E-10 1.0293059
ENSG00000123416 TBAK_HUMAN 6.1972505E-10 1.0070857
ENSG00000172216 CEBPB 7.545418E-10 0.7460686
P-values of the Wilcoxon test for the bands of chromosome  9 Figure 8
P-values of the Wilcoxon test for the bands of chro-
mosome 9. This figure plots the bands of chromosome 9 on 
the x-axis against the p-values of the Wilcoxon test (y-axis), 
which tested each band between the two groups "s" and "b". 
The p-values of the first four bands 9p24, 9p23, 9p22, 9p21 
are very small, compared to the remaining ones. This affirms 
the proposed subgroups "s" and "b" and indicates that the 
first four bands have a relation to this classification.
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eration genes differentially implicated in MCL prognosis
such as SOCS1 and CEBPB.
The Wilcoxon rank sum test revealed relations between
the bands 9p24, 9p23, 9p22 and 9p21 and the difference
between the longer and shorter living patients. Investiga-
tion of those bands regarding most significant differen-
tially expressed genes revealed a cluster of genes with
properties such as "differentiation blocking", "anti apop-
totic" and "apoptosis inducing". Supporting our finding,
the band 9p21 was suggested be implicated in MCL
patient outcome [56]. Some bands of chromsome 7 iden-
tified further expression differences somewhat weaker
associated with the outcome. As the annotation and prop-
erties of embedded genes are not completely known, fur-
ther data are required to better explain the relation
between gene functions and survival. CGH data may
improve the power of gene expression based predictors
[57]. Besides others, the band 9p21 was associated with a
poor clinical outcome, which affirms our finding.
Our study extends these CGH results in two ways: (i)
exploratory analysis shows here for the first time, that in
fact CGH data alone can predict prognosis in MCL, (ii)
CGH data point here directly to several genes regulated
differently in good or bad prognosis patients.
Conclusion
After careful re-annotation of involved genes we found
two subgroups of MCL patients which were found and
supported by exploratory analysis of gene expression val-
ues and CGH data, network analysis and literature min-
ing. We obtained an improved classification of MCL
regarding prognosis. Differentially expressed genes
formed a tight protein interaction network of kinases. A
seven gene predictor appeared as an easy to measure prog-
nosis indicator for clinical use. The Wilcoxon rank sum
test as well as PCA was applied successfully to a CGH data
set in this study. Both identify bands on chromosome 9.
Following the indicated bands, we found differentially
expressed MCL related genes.
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Correspondence analysis of chromosome 9 over the "s" and "b" group. 
The first order factor axis separates almost completely these two groups. It 
is also obvious that the first four bands 9p24, 9p23, 9p22, 9p21 attract 
most of all b-patients. This leads to the assumption, that these four bands 
are responsible for the difference of the longer living "s" and the shorter 
living "b" patients. The second order factor axis separates at first glance 
strongly the last two bands 9q33, 9q34 from the rest.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-8-106-S1.pdf]
Table 4: The best "s" and "b" separating genes of chromosome 9 bands 9p24, 9p21, 9q33, and 9q34
Gene Start bp. End bp. Fold change p-value Official full name
HSPA5 127036953 127043430 0.4364743 0.03039 Heat shock 70 kDa protein 5
PPP6C 126948673 126991918 0.2798860 0.03385 Protein phosphatase 6, catalytic subunit
PBX3 127548372 127769477 0.3976210 0.03385 Pre-B-cell leukemia homeobox 3
PTGS1 124173050 124197803 0.4124149 0.03927 Prostaglandin-endoperoxide synthase 1
QSCN6L1 138240395 138277470 -0.3886557 0.03927 Quiescin Q6 sulfhydryl oxidase 2
A moderate t-test revealed the following ones as the genes with the highest significance. Although the significance is weak, it is quite remarkable 
that these genes here show a distinct clustering on the basis of genomic positions [see Additional file 4].BMC Cancer 2008, 8:106 http://www.biomedcentral.com/1471-2407/8/106
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